- recruitingPHASE1, PHASE2
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
This study is testing a new medicine, ALETA-001, for people with certain types of B-cell lymphoma. It's for those who have already had a specific CAR T-cell treatment. The study will look at how safe and effective ALETA-001 is.
United Kingdom - not yet recruitingPHASE1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This study is testing a new drug, LY4152199, for people with certain types of B-cell lymphoma that have returned or not responded to previous treatments. Researchers want to find the best dose and see how safe and effective it is.
United States · Australia · Canada - active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
United States · Australia · Austria - active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
United States · Argentina · Australia